AstraZeneca Reports Results of Brilinta (ticagrelor) in P-III THEMIS Study for Coronary Artery Disease and Type-2 Diabetes
Shots:
- The P-III THEMIS study involves assessing of Brilinta + Aspirin vs Aspirin as monothx. in 19-000+ patients with CAD and T2D with no prior myocardial infarction or stroke across 42 countries including EU- Asia- Africa- North and South America
- The P-III THEMIS study results demonstrated 10% reduction in risk of CV deaths- heart attacks and stroke- 15% reduction in risk in a prespecified sub-analysis of patients who had undergone percutaneous coronary intervention
- Brilinta is a reversible- direct-acting P2Y12 receptor antagonist- act by inhibiting platelet activation- co-administered with aspirin for the prevention of atherothrombotic events in patients with ACS/prior having MI and a high risk of developing an atherothrombotic event
Click here to read full press release/ article
Ref: AstraZeneca | Image: AstraZeneca
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com